METTL3 and IGF2BP1-Mediated m6A Modification of ZHX2 Promotes Tumor Property of Renal Cell Carcinoma
Kidney and Blood Pressure Research · 2024
DOI: 10.1159/000540483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Bangming Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan City, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Methyltransferases, Kidney Neoplasms, RNA-Binding Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Renal cell carcinoma (RCC) is a common type of kidney cancer with limited treatment options and a high mortality rate. Therefore, it is essential to understand the role and mechanism of key genes in RCC development and progression. This study aimed to analyze the role of zinc fingers and homeoboxes 2 (ZHX2) in RCC and the underlying mechanism.
Methods
RNA expression was analyzed by quantitative real-time polymerase chain reaction, while protein expression was analyzed by Western blotting assay and immunohistochemistry assay. Cell viability was evaluated using CCK-8 assay, and cell proliferation was assessed by EdU assay. The rate of cell apoptosis was quantified by flow cytometry. Transwell assays were conducted to analyze cell migration and invasion. The sphere formation assay was performed to assess the formation of microspheres. Additionally, m6A RNA immunoprecipitation assay and RNA immunoprecipitation assay were utilized to investigate the relationship between ZHX2 and two proteins, methyltransferase like 3 (METTL3) and insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1). The stability of ZHX2 mRNA was analyzed through the Actinomycin D assay. Furthermore, a xenograft mouse model assay was conducted to analyze the effect of ZHX2 overexpression and METTL3 silencing on RCC cell tumor properties in vivo.
Results
ZHX2 expression was upregulated in both RCC tissues and cells when compared with healthy renal tissues and human renal cortex proximal convoluted tubule epithelial cells. Depletion of ZHX2 inhibited RCC cell proliferation, migration, invasion, and spheroid-forming capacity but promoted cell apoptosis. Moreover, it was found that METTL3-mediated m6A methylation of ZHX2 and IGF2BP1 also stabilized ZHX2 through m6A methylation modification. Furthermore, ZHX2 overexpression showed a potential for attenuating the effects induced by METTL3 silencing and counteracted the inhibitory effect of METTL3 depletion on tumor formation in vivo.
Conclusion
METTL3 and IGF2BP1-mediated m6A modification of ZHX2 promoted RCC progression. The finding suggests that ZHX2 may serve as a potential therapeutic target in RCC, providing valuable insights for future clinical interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan City, China.
- Reproductive Medicine Laboratory Center, Taihe Hospital, Hubei University of Medicine, Shiyan City, China.
Zitieren
APA
Xiao, B., Li, Y., Yang, Y., Chen, C., Gong, S., Li, H., Yao, Q., & Wang, L. (2024). METTL3 and IGF2BP1-Mediated m6A Modification of ZHX2 Promotes Tumor Property of Renal Cell Carcinoma. Kidney and Blood Pressure Research. https://doi.org/10.1159/000540483
Vancouver
Xiao B, Li Y, Yang Y, Chen C, Gong S, Li H, et al. METTL3 and IGF2BP1-Mediated m6A Modification of ZHX2 Promotes Tumor Property of Renal Cell Carcinoma. Kidney and Blood Pressure Research. 2024. doi:10.1159/000540483
BibTeX
@article{Xiao2024,
author = {Xiao, Bangming and Li, Yalan and Yang, Yong and Chen, Congbo and Gong, Shide and Li, Hao and Yao, Qisheng and Wang, Li},
title = {METTL3 and IGF2BP1-Mediated m6A Modification of ZHX2 Promotes Tumor Property of Renal Cell Carcinoma},
journal = {Kidney and Blood Pressure Research},
year = {2024},
doi = {10.1159/000540483}
}
EUVIMED